Argonaut Manufacturing Services opens custom controls & standards facility
The CMO has designed the new service to alleviate manufacturing challenges associated with positive controls and nucleic acid templates
Argonaut Manufacturing Services, a contract manufacturing organization for Life Science, Diagnostic, and BioPharma markets, has launched a new service offering to support the growing need for custom controls, standards and verification panels.
Formulating and filling these products will be performed at a new standalone facility in Carlsbad, California.
The company said the site has been designed to alleviate many of the concerns expressed with the manufacturing challenges associated with positive controls and nucleic acid templates.
Controls and standards are used regularly by innovators to verify instruments, reagents, and diagnostic tests to ensure standard operating procedures (SOPs) are followed properly for patient samples.
The Custom Molecular Controls and Standards service provides organizations focusing on diagnostics for the regulated markets and RUO (research use only) assays, a complete solution for their commercial products with Argonaut and controls that match the same quality standards that Argonaut Manufacturing Services provides.
“This service offering has been widely requested by our clients in every market from Point of Care device makers to platform companies,” said Wayne Woodard, CEO of Argonaut.
The CMO's new offering provides a wide range of solutions including synthetic PCR controls, antibodies, buffers, and markers. Controls and standards can also be lyophilized to both extend shelf-life and improve protocols.
Rather than being restricted to off-the-shelf controls or putting in the capital equipment and labour-intensive SOPs to manufacture their own controls, clients can quickly add controls that are specific for their assays.
Eric Blair, COO of Argonaut, said that with the company's strength in lyophilization, its Custom Molecular Controls and Standards service offers opportunities for improving assays by reducing waste due to shelf-life issues, and simplifying protocols by reducing pipetting and mixing steps.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...